Clinical-stage biopharmaceutical company SpringWorks Therapeutics, a developer of medicines for patients with severe rare diseases and cancer, revealed on Wednesday that its gamma-secretase inhibitor Nirogacestat has received Fast Track designation from the US Food and Drug Administration (FDA).
SpringWorks Therapeutics said the FDA Fast Track program is designed to expedite the development and review of drugs with the potential to treat serious or life-threatening conditions and with nonclinical or clinical data that demonstrate the potential to address unmet medical needs. This designation enables a company to have frequent communication with the FDA throughout the drug development and review process.
Nirogacestat is an investigational, oral, small molecule, selective gamma-secretase inhibitor used to treat adult patients with progressive, unresectable, recurrent or refractory desmoid tumours or deep fibromatosis.
According to SpringWorks Therapeutics, desmoid tumors are rare and debilitating soft-tissue tumours that can occur in both children and adults. Depending on the size and location, desmoid tumours can cause severe morbidities such as pain, internal bleeding, disfigurement and limited range-of-motion. Desmoid tumours can be fatal if they impact vital organs.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML